[go: up one dir, main page]

AR053416A1 - Combinacion de glicoisoformas para el tratamiento o prevencion de la septicemia, linea celular transgenica productora de glicoformas de eritropoyetina, composicion farmaceutica que comprende a dicha combinacion, procedimientos para obtener la linea celular, procedimiento para producir dicha combinac - Google Patents

Combinacion de glicoisoformas para el tratamiento o prevencion de la septicemia, linea celular transgenica productora de glicoformas de eritropoyetina, composicion farmaceutica que comprende a dicha combinacion, procedimientos para obtener la linea celular, procedimiento para producir dicha combinac

Info

Publication number
AR053416A1
AR053416A1 ARP050104712A ARP050104712A AR053416A1 AR 053416 A1 AR053416 A1 AR 053416A1 AR P050104712 A ARP050104712 A AR P050104712A AR P050104712 A ARP050104712 A AR P050104712A AR 053416 A1 AR053416 A1 AR 053416A1
Authority
AR
Argentina
Prior art keywords
combination
cellular
septicemia
procedures
prevention
Prior art date
Application number
ARP050104712A
Other languages
English (en)
Inventor
Marcelo Daelli
Bacci Dardo Alexis Pereira
Gabriel Ignacio Amadeo
Miriam Patricia Pereira
Cristina Noemi Artana
Nestor Maskin
Bernardo Cesar Pistillo
Original Assignee
Protech Pharma S A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Protech Pharma S A filed Critical Protech Pharma S A
Priority to ARP050104712A priority Critical patent/AR053416A1/es
Priority to CA2629304A priority patent/CA2629304C/en
Priority to ZA200805044A priority patent/ZA200805044B/xx
Priority to ES06820043T priority patent/ES2396439T3/es
Priority to EP06820043A priority patent/EP1947115B1/en
Priority to US12/093,365 priority patent/US8343917B2/en
Priority to BRPI0618498-7A priority patent/BRPI0618498A2/pt
Priority to MX2008006159A priority patent/MX2008006159A/es
Priority to PCT/ES2006/070171 priority patent/WO2007054600A2/es
Priority to AU2006313672A priority patent/AU2006313672B2/en
Publication of AR053416A1 publication Critical patent/AR053416A1/es
Priority to IL191279A priority patent/IL191279A/en
Priority to MA30921A priority patent/MA30010B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1816—Erythropoietin [EPO]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7012—Compounds having a free or esterified carboxyl group attached, directly or through a carbon chain, to a carbon atom of the saccharide radical, e.g. glucuronic acid, neuraminic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/02—Cells for production

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Combinacion de glicoisoformas de eritropoyetina, en donde dichas glicoisoformas pueden comprender una cantidad de ácido siálico de entre 4 a 10 moléculas de ácido siálico por molécula de eritropoyetina, la combinacion de glicoisoformas se puede usar para el tratamineto o prevencion de la septicemia/sepsis, una composicion farmacéutica que comprende a dicha combinacion, una línea celular productora de una combinacion de glicosoformas de eritropoyetina, procedimientos para obtener la línea celular, procedimientos para obtener la línea celular, procedimiento para producir dicha combinacion de glicoisoformas y métodos de tratamiento y prevencion de la septiciemia/sepsis.
ARP050104712A 2005-11-10 2005-11-10 Combinacion de glicoisoformas para el tratamiento o prevencion de la septicemia, linea celular transgenica productora de glicoformas de eritropoyetina, composicion farmaceutica que comprende a dicha combinacion, procedimientos para obtener la linea celular, procedimiento para producir dicha combinac AR053416A1 (es)

Priority Applications (12)

Application Number Priority Date Filing Date Title
ARP050104712A AR053416A1 (es) 2005-11-10 2005-11-10 Combinacion de glicoisoformas para el tratamiento o prevencion de la septicemia, linea celular transgenica productora de glicoformas de eritropoyetina, composicion farmaceutica que comprende a dicha combinacion, procedimientos para obtener la linea celular, procedimiento para producir dicha combinac
US12/093,365 US8343917B2 (en) 2005-11-10 2006-11-07 Combination of erythropoietin glycoisoforms
ZA200805044A ZA200805044B (en) 2005-11-10 2006-11-07 Combination of glycoisoforms for the treatment or prevention of septicemia, transgenic cell line that produces erythropoietin glycoisoforms, pharmaceutical composition comprising said combination
ES06820043T ES2396439T3 (es) 2005-11-10 2006-11-07 Combinación de glicoisoformas para el tratamiento o la prevención de la septicemia, línea celular transgénica que produce glicoisoformas de eritropoyetina, composición farmacéutica que comprende dicha combinación, procedimiento para obtener la línea celular, procedimiento para producir la combinación de glicoisoformas y procedimientos para el tratamiento y la prevención de la septicemia
EP06820043A EP1947115B1 (en) 2005-11-10 2006-11-07 Combination of glycoisoforms for the treatment or prevention of septicemia, transgenic cell line that produces erythropoietin glycoisoforms, pharmaceutical composition comprising said combination, method of obtaining the cell line, method of producing the combination of glycoisoforms and methods for the treatment and prevention of septicaemia
CA2629304A CA2629304C (en) 2005-11-10 2006-11-07 Combination of glycoisoforms for the treatment or prevention of septicemia, transgenic cell line that produces erythropoietin glycoisoforms, pharmaceutical composition comprising said combination
BRPI0618498-7A BRPI0618498A2 (pt) 2005-11-10 2006-11-07 combinação de glicoisoformas para o tratamento ou a prevenção da septicemia, linha celular transgênica produtora de glicoformas de eritropoietina, composição farmacêutica incluindo tal combinação, procedimentos para obtenção da linha celular, procedimentos para produção de tal combinação de glicoisoformas e métodos para tratamento e prevenção da septicemia
MX2008006159A MX2008006159A (es) 2005-11-10 2006-11-07 Combinacion de glicoisoformas para el tratamiento o prevencion de la septicemia, linea celular transgenica productora de glicoformas de eritropoyetina, composiciones farmaceutica que comprende a dicha combinacion, procedimientos para obtener la linea
PCT/ES2006/070171 WO2007054600A2 (es) 2005-11-10 2006-11-07 Combinación de glicoisoformas para el tratamiento o prevención de la septicemia, línea celular transgénica productora de glicoformas de eritropoyetina, composición farmacéutica que comprende a dicha combinación
AU2006313672A AU2006313672B2 (en) 2005-11-10 2006-11-07 Combination of glycoisoforms for the treatment or prevention of sepsis, transgenic cell line producing erythropoietin glycoisoforms, pharmaceutical composition comprising such combination, procedures to obtain the cell line, procedures to produce such combination of glycoisoforms, and sepsis treatment and prevention methods
IL191279A IL191279A (en) 2005-11-10 2008-05-06 Combination of glycoisoforms for the treatment or prevention of sepsis, transgenic cell line producing erythropoietin glycoisoforms, pharmaceutical compositions comprising such combination, procedures to obtain the cell line and procedures to produce such combination of glycoisoforms
MA30921A MA30010B1 (fr) 2005-11-10 2008-05-09 Combinaison de glyco-isoformes destinees au traitement ou a la prevention de la septicemie, lignee cellulaire transgenique produisant des glycoformes d'erythropoïetine, composition pharmaceutique renfermant ladite combinaison, procede pour produire ladite combinaison de glyco-isoformes et methodes destinees au traitement ou a la prevention de la septicemie

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ARP050104712A AR053416A1 (es) 2005-11-10 2005-11-10 Combinacion de glicoisoformas para el tratamiento o prevencion de la septicemia, linea celular transgenica productora de glicoformas de eritropoyetina, composicion farmaceutica que comprende a dicha combinacion, procedimientos para obtener la linea celular, procedimiento para producir dicha combinac

Publications (1)

Publication Number Publication Date
AR053416A1 true AR053416A1 (es) 2007-05-09

Family

ID=38023621

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP050104712A AR053416A1 (es) 2005-11-10 2005-11-10 Combinacion de glicoisoformas para el tratamiento o prevencion de la septicemia, linea celular transgenica productora de glicoformas de eritropoyetina, composicion farmaceutica que comprende a dicha combinacion, procedimientos para obtener la linea celular, procedimiento para producir dicha combinac

Country Status (12)

Country Link
US (1) US8343917B2 (es)
EP (1) EP1947115B1 (es)
AR (1) AR053416A1 (es)
AU (1) AU2006313672B2 (es)
BR (1) BRPI0618498A2 (es)
CA (1) CA2629304C (es)
ES (1) ES2396439T3 (es)
IL (1) IL191279A (es)
MA (1) MA30010B1 (es)
MX (1) MX2008006159A (es)
WO (1) WO2007054600A2 (es)
ZA (1) ZA200805044B (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112741895A (zh) * 2021-01-19 2021-05-04 中国人民解放军陆军军医大学 Epo类似物在制备治疗脓毒症药物中的应用

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL77081A (en) 1984-12-04 1999-10-28 Genetics Inst Dna sequence encoding human erythropoietin process for the preparation thereof and a pharmaceutical composition of human erythropoietin
DE3923963A1 (de) 1989-07-20 1991-01-31 Behringwerke Ag Muteine des menschlichen erythropoetins, ihre herstellung und ihre verwendung
US5856298A (en) 1989-10-13 1999-01-05 Amgen Inc. Erythropoietin isoforms
TW586933B (en) 1996-06-20 2004-05-11 Chugai Pharmaceutical Co Ltd Compositions for treating liver-complaints using EPO
US6165783A (en) 1997-10-24 2000-12-26 Neuro Spheres Holdings Ltd. Erythropoietin-mediated neurogenesis
DE59813187D1 (de) 1997-12-03 2005-12-15 Roche Diagnostics Gmbh Verfahren zur herstellung von polypeptiden mit geeigneter glykosilierung
US20020169129A1 (en) 1998-02-04 2002-11-14 Zaharia Veronica C. Method for improving the quality of life of patients by administration of erythropoietin (RhuEPO)
US6310078B1 (en) 1998-04-20 2001-10-30 Ortho-Mcneil Pharmaceutical, Inc. Substituted amino acids as erythropoietin mimetics
BR9917606A (pt) * 1998-11-06 2002-12-31 Bio Sidus S A Procedimento para a purificação de eritropoetina humana recombinante a partir de sobrenadantes de cultivo de células e eritropoetina humana recombinante obtida com tal procedimento
CA2370477C (en) * 1999-04-15 2010-06-29 Crucell Holland B.V. Recombinant protein production in a human cell using sequences encoding adenovirus e1 protein
US7297680B2 (en) * 1999-04-15 2007-11-20 Crucell Holland B.V. Compositions of erythropoietin isoforms comprising Lewis-X structures and high sialic acid content
US6531121B2 (en) 2000-12-29 2003-03-11 The Kenneth S. Warren Institute, Inc. Protection and enhancement of erythropoietin-responsive cells, tissues and organs
US7767643B2 (en) * 2000-12-29 2010-08-03 The Kenneth S. Warren Institute, Inc. Protection, restoration, and enhancement of erythropoietin-responsive cells, tissues and organs
MXPA03006990A (es) 2001-02-06 2003-11-18 Merck Patent Gmbh Eritropoyetina (epo) modificada con inmunogenicidad reducida.
CA2756610C (en) * 2001-10-29 2015-08-25 Crucell Holland B.V. Methods for producing proteins having n-linked glycans comprising (sialyl-) lewis x or lacdinac structures
US6784154B2 (en) 2001-11-01 2004-08-31 University Of Utah Research Foundation Method of use of erythropoietin to treat ischemic acute renal failure
CN1596310A (zh) 2001-11-28 2005-03-16 桑多斯有限公司 产生重组多肽的方法
AU2002356749A1 (en) 2001-11-28 2003-06-10 Hermann Katinger Process for the production of polypeptides in mammalian cell cultures
CA2476538C (en) 2002-01-09 2012-07-17 Crucell Holland B.V. Use of erythropoietin for the preventive or curative treatment of cardiac failure
SI1492878T1 (sl) 2002-03-26 2007-12-31 Lek Pharmaceutical And Chemical Co. D.D. Postopek za pripravo Ĺľelenega profila gliko-izoform eritropoietina
US7300915B2 (en) 2002-06-05 2007-11-27 The Regents Of The University Of California Use of erythropoietin and erythropoietin mimetics for the treatment of neuropathic pain
DE10234192B4 (de) 2002-07-26 2009-11-26 Epoplus Gmbh Co.Kg Verwendung von Erythropoetin
US20040091961A1 (en) 2002-11-08 2004-05-13 Evans Glen A. Enhanced variants of erythropoietin and methods of use
US20040198663A1 (en) 2003-04-04 2004-10-07 Baker John E. Method of treating cardiac ischemia by using erythropoietin
KR20060032140A (ko) 2003-05-30 2006-04-14 센토코 인코포레이티드 트랜스글루타미나아제를 이용한 신규 에리트로포이에틴접합체의 형성

Also Published As

Publication number Publication date
BRPI0618498A2 (pt) 2011-09-06
WO2007054600B1 (es) 2007-10-18
US8343917B2 (en) 2013-01-01
ES2396439T3 (es) 2013-02-21
ZA200805044B (en) 2009-08-26
CA2629304C (en) 2012-12-04
CA2629304A1 (en) 2007-05-18
AU2006313672B2 (en) 2011-12-08
AU2006313672A1 (en) 2007-05-18
EP1947115B1 (en) 2012-10-17
US20090220595A1 (en) 2009-09-03
IL191279A (en) 2012-05-31
MA30010B1 (fr) 2008-12-01
WO2007054600A3 (es) 2007-07-19
EP1947115A2 (en) 2008-07-23
MX2008006159A (es) 2008-10-09
WO2007054600A2 (es) 2007-05-18
EP1947115A4 (en) 2010-03-03

Similar Documents

Publication Publication Date Title
NO20082240L (no) GLP-2 imitatorstoff, polypeptider, sammensetninger, fremgangsmater og anvendelser
CY1110860T1 (el) Αναστροφη μεταγραφαση τελομερασης πτηνου
ES2542853T3 (es) Método para tratar miastenia grave
CL2011000207A1 (es) Composicion biocida que comprende ciprodinil y flutianil; metodo para controlar enfermedades en plantas utiles o en material de propagacion causadas por fitopatogenos (div. sol. n°2602-06).
DOP2009000269A (es) Anticuerpos humanizados contra el globulomero ab(20-42) y sus usos
AR069860A1 (es) Metodo para purificar un anticuerpo cd20
AR056055A1 (es) Complejos cristalinos e hidratos de 1-cloro-4-(beta-d-glucopiranos-1-il)-2-(4-etinil-bencil)-benceno
DK1841756T3 (da) 3-heterocyclyl-3-hydroxy-2-amino-propionisyre-amider og relaterede forbindelser med analgesisk og/eller immunostimulatorisk aktivitet
CL2012002522A1 (es) Composición farmacéutica que comprende un compuesto inhibidor de dpp iv con un grupo amino o una sal del mismo , un primer diluyente , un segundo diluyente ,un aglutinante , un disgregante y un lubricante, útil en el tratamiento de diabetes mellitus.
BRPI0601896A (pt) composições que contêm microgéis e agentes espessantes
BRPI0703700A (pt) nanopartìculas contendo prata com estabilizador de substituição
AR063972A1 (es) Plantas con rasgos mejorados relacionados con el rendimiento y un metodo para producirlas
DK1945228T3 (da) Sulfoalkyl-ether-cyclodextrin-sammensætninger og fremgangsmåder til fremstilling deraf
GT200600520A (es) Agentes antibacterianos
GT200800115A (es) Metodos para tratar infecciones del tracto gastrointestinal con tigeciclina
PE20110677A1 (es) Polimorfo b de la n-(2-aminofenil)-4-[n-(piridin-3-il) metoxicarbonilamino-metil]benzamida (ms-275)
GT200500246A (es) Combinacion de compuestos organicos
ATE531715T1 (de) 1,3-dihydro-2h-pyrroloä3.2-büpyridin-2-onderiva e,deren herstellung und deren therapeutische verwendungen
ES2421915T3 (es) Derivados de amida del ácido hialurónico en osteoartrosis
AR056835A1 (es) Composicion que contiene oligosacaridos
AR053416A1 (es) Combinacion de glicoisoformas para el tratamiento o prevencion de la septicemia, linea celular transgenica productora de glicoformas de eritropoyetina, composicion farmaceutica que comprende a dicha combinacion, procedimientos para obtener la linea celular, procedimiento para producir dicha combinac
NO20074528L (no) Substituerte pyrroler, sammensetninger, fremgangsmate for fremstilling og anvendelse av samme
CL2008000707A1 (es) Conjugado de polipeptidos antifusogenicos y polipeptidos derivados de la cabeza globular del factor del complemento c1q; composicion farmaceutica que lo comprende; su uso para tratar infecciones viricas; y metodo de produccion.
NO20091386L (no) Fenyloksyanilinderivater
ATE449940T1 (de) Kühlvorrichtung

Legal Events

Date Code Title Description
FB Suspension of granting procedure